checkAd
    Startseite > Aktien > 89bio > Nachrichten
    89bio Aktie
    8,3200
     
    USD
    +2,21 %
    +0,1800 USD
    Letzter Kurs 28.05.24 Nasdaq
    8,3100
     
    USD
    20.300 STK
    Geldkurs 28.05.24
    8,3200
     
    USD
    4.800 STK
    Briefkurs 28.05.24
    ISIN: US2825591033 · WKN: A2PUP8 · SYM: ETNB · USA

    Neueste Nachrichten

    89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
    22.05.24 · globenewswire · 89bio
    89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
    14.05.24 · globenewswire · 89bio
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    10.05.24 · globenewswire · 89bio
    89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
    09.05.24 · globenewswire · 89bio
    89bio to Participate in the BofA Securities 2024 Health Care Conference
    08.05.24 · globenewswire · 89bio
    89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
    02.05.24 · globenewswire · 89bio
    89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
    17.04.24 · globenewswire · 89bio
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    05.04.24 · globenewswire · 89bio
    89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
    27.03.24 · globenewswire · 89bio
    89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
    12.03.24 · globenewswire · 89bio
    89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    08.03.24 · globenewswire · 89bio
    89bio to Participate in the Leerink Partners Global Biopharma Conference
    05.03.24 · globenewswire · 89bio